Top

Published in:

01-12-2019 | Breast Cancer | Review

Obstetrical outcomes in women with history of breast cancer: a systematic review and meta-analysis

Authors: Valentina D’Ambrosio, Flaminia Vena, Daniele Di Mascio, Ida Faralli, Lucia Musacchio, Chiara Boccherini, Roberto Brunelli, Maria Grazia Piccioni, Pierluigi Benedetti Panici, Antonella Giancotti

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Abstract

Purpose

Potential risk of adverse obstetrical outcomes has been shown among breast cancer survivors. Therefore, the aim of this systematic review and meta-analysis was to evaluate the relationship between history of breast cancer (BC) and obstetrical outcomes.

Methods

PubMed, EMBASE, and Medline were searched from the inception of each database to April 2019. Selection criteria included prospective and retrospective cohort studies of BC pregnant survivors. The meta-analysis was performed by computing odds ratios (ORs) using both fixed and random-effects models. Quality assessment of the included studies was performed using the Newcastle–Ottawa Scale and the review was registered with PROSPERO number CRD42019127716.

Results

Four studies, including 1466 cases of BC survivors and 6,912,485 controls, were included. Compared with controls, a higher incidence of obstetrical complication was found in women with history of BC. The incidence of preterm birth (PTB) in the study group was 11.05% compared with 7.79% in the control group (1.68, 95% confidence interval 1.43–1.99). Breast cancer history was also associated with low birth weight (LBW) (study group: 9.26% vs. control group: 5.54%, 1.88, CI 95% 1.55–2.27), cesarean section (CS) (study group: 19.76% vs. control group 10.81%, 1.78, CI 95% 1.39–2.27), intrauterine fetal death (IUFD) (study group: 0.004% vs. control group 0.36%, of 1.25 CI 95% 0.36–4.35), and fetal anomalies (study group: 5.8% vs. control group: 4.26%, 1.45 CI 95% 1.01–2.09).

Conclusions

History of BC was associated with adverse obstetrical outcomes.

Available only for authorised users

World Cancer Research Fund International (2015) Breast cancer statistics [Internet]. http://www.wcrf.org. Accessed 3 March 2019

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr. Accessed 2 March 2019

Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev 25(1):16–27CrossRef

Ginsburg O, Bray F, Coleman MP et al (2016) The global burden of women’s cancers: a grand challenge in global health. Lancet 389:847–860. https://doi.org/10.1016/S0140-6736(16)31392-7 CrossRefPubMedPubMedCentral

DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. Cancer J Clin 66(1):31–42. https://doi.org/10.3322/caac.21320 CrossRef

Howlader NNA, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2016) Cancer Statistics Review, 1975^2013çSEER Statistics. Based on November 2015 SEER data submission. https://seer.cancer.gov/csr/1975_2013/. Accessed 3 February 2019

Estimated Number of New Cases for the Four Major Cancers by Sex and Age Group (2018) American Cancer Society, Surveillance Research. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/estimated-number-of-new-cases-for-the-four-major-cancers-by-sex-and-age-group-2018.pdf. Accessed 13 Dec 2018

Kroman N, Jensen M-B, Wohlfahrt J, Ejlertsen B, Danish Breast Cancer Cooperative Group (2008) Pregnancy after treatment of breast cancer—a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol Stockh Swed 47:545–549. https://doi.org/10.1080/02841860801935491 CrossRef

Shah NM, Scott DM, Kandagatla P, Moravek MB, Cobain EF, Burness ML et al (2019) Young women with breast cancer: fertility preservation options and management of pregnancy-associated breast cancer. Ann Surg Oncol. https://doi.org/10.1245/s10434-019-07156-7 CrossRefPubMedPubMedCentral

10.

Langagergaard V, Gislum M, Skriver MV et al (2006) Birth outcome in women with breast cancer. Br J Cancer 94:142–146. https://doi.org/10.1038/sj.bjc.6602878 CrossRefPubMedPubMedCentral

11.

Dalberg K, Eriksson J, Holmberg L (2006) Birth outcome in women with previously treated breast cancer—a population-based cohort study from Sweden. PLoS Med 3:e336. https://doi.org/10.1371/journal.pmed.0030336 CrossRefPubMedPubMedCentral

12.

Langagergaard V (2010) Birth outcome in women with breast cancer, cutaneous malignant melanoma, or Hodgkin’s disease: a review. Clin Epidemiol 3:7–19. https://doi.org/10.2147/CLEP.S12190 CrossRefPubMedPubMedCentral

13.

Ramírez-Torres N, Robles-Robles AG, Villafaña-Vázquez VH et al (2010) Breast cancer and subsequent pregnancy. Infertility, death risk and survival [in Spanish]. Ginecol Obstet Mex 78:85–93PubMed

14.

Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC (2010) How to write a Cochrane systematic review. Nephrology (Carlton) 15:617–624. https://doi.org/10.1111/j.1440-1797.2010.01380.x CrossRef

15.

NHS Centre for Reviews and Dissemination (2009) Systematic reviews: CRD’s guidance forundertaking reviews in health care. University of York, York. https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf. Retrieved from 3 Dec 2016

16.

Welch V, Petticrew M, Petkovic J et al (2016) Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration. J Clin Epidemiol 70:68–89. https://doi.org/10.1016/j.jclinepi.2015.09.001 CrossRefPubMed

17.

Stewart LA, Clarke M, Rovers M et al (2015) Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA 313:1657–1665. https://doi.org/10.1001/jama.2015.3656 CrossRefPubMed

18.

Wells GA, Shea B, O’Connell D, et al (2018) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses. Ottawa Hospital Research Institute, Ottawa. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 27 Feb 2018

19.

Higgins JPT, Thompson SG, Deeks JJ, Altman DJ (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557 CrossRefPubMedPubMedCentral

20.

Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315(7121):1533–1537. https://doi.org/10.1136/bmj.315.7121.1533 CrossRefPubMedPubMedCentral

21.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRef

22.

Jacob L, Kalder M, Arabin B, Kostev K (2017) Impact of prior breast cancer on mode of delivery and pregnancy-associated disorders: a retrospective analysis of subsequent pregnancy outcomes. J Cancer Res Clin Oncol 143:1069–1074. https://doi.org/10.1007/s00432-017-2352-3 CrossRefPubMed

23.

Hartnett KP, Ward KC, Kramer MR, Lash TL, Mertens AC, Spencer JB, Fothergill A, Howards PP (2017) The risk of preterm birth and growth restriction in pregnancy after cancer. Int J Cancer 141(11):2187–2196. https://doi.org/10.1002/ijc.30914 CrossRefPubMedPubMedCentral

24.

Iqbal J, Amir E, Rochon PA, Giannakeas V, Sun P, Narod SA (2017) Association of the timing of pregnancy with survival in women with breast cancer. JAMA Oncol 3(5):659–665. https://doi.org/10.1001/jamaoncol.2017.0248 CrossRefPubMedPubMedCentral

25.

Azim HA Jr, Kroman N, Paesmans M et al (2013) Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 31:73. https://doi.org/10.1200/JCO.2012.44.2285 CrossRefPubMed

26.

Black KZ, Nichols HB, Eng E, Rowley DL (2017) Prevalence of preterm, low birthweight, and small for gestational age delivery after breast cancer diagnosis: a population-based study. Breast Cancer Res 19(1):11. https://doi.org/10.1186/s13058-017-0803-z CrossRefPubMedPubMedCentral

27.

Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S (2007) The role of inflammation and infection in preterm birth. Semin Reprod Med 25(1):21–39. https://doi.org/10.1055/s-2006-956773 CrossRefPubMed

28.

Hakim FT, Cepeda R, Kaimei S et al (1997) Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 90(9):3789–3798CrossRef

29.

Wiser I, Orr N, Kaufman B et al (2010) Immunosuppressive treatments reduce long-term immunity to smallpox among patients with breast cancer. J Infect Dis 201(10):1527–1534. https://doi.org/10.1086/651950 CrossRefPubMed

30.

Signorello LB, Mulvihill JJ, Green DM et al (2010) Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. Lancet 376:624. https://doi.org/10.1016/S0140-6736(10)60752-0 CrossRefPubMedPubMedCentral

31.

Winther JF, Olsen JH, Wu H et al (2012) Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol 30:27. https://doi.org/10.1200/JCO.2011.35.0504 CrossRefPubMed

32.

Signorello LB, Mulvihill JJ, Green DM et al (2012) Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol 30:239. https://doi.org/10.1200/JCO.2011.37.2938 CrossRefPubMed

33.

Green DM, Peabody EM, Nan B et al (2002) Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 20:2506. https://doi.org/10.1200/jco.2002.07.159 CrossRefPubMed

34.

Ståhl O, Boyd HA, Giwercman A et al (2011) Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst 103:398. https://doi.org/10.1093/jnci/djq550 CrossRefPubMedPubMedCentral

35.

Witt KL, Bishop JB (1996) Mutagenicity of anticancer drugs in mammalian germ cells. Mutat Res 355(1–2):209–234CrossRef

36.

Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R (2011) Use of tamoxifen before and during pregnancy. Oncologist 16(11):1547–1551CrossRef

37.

Momen NC, Ernst A, Arendt LH et al (2017) Maternal cancer and congenital anomalies in children—a Danish nationwide cohort study. PLoS ONE 12(3):e0173355CrossRef

Title: Obstetrical outcomes in women with history of breast cancer: a systematic review and meta-analysis
Authors: Valentina D’Ambrosio
Flaminia Vena
Daniele Di Mascio
Ida Faralli
Lucia Musacchio
Chiara Boccherini
Roberto Brunelli
Maria Grazia Piccioni
Pierluigi Benedetti Panici
Antonella Giancotti
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Breast Cancer
Premature Birth
Sectio Ceasarea
Breast Cancer
Sectio Caesarea
Published in: Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05408-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy

Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina

The microbiome and breast cancer: a review

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

BCRT: a brief valedictory

Keynote webinar | Spotlight on antibody–drug conjugates in cancer